UNSPSC 51292010: Flunamine

This classification denotes a nonsteroidal antiinflammatory drug and antiparkinsonian agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IZ1GXE233H. European Medicines Agency schedules Flunamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07706MIG. Flunamine generally arises in the molecular formula C15H15F2NO.

UNSPSC 51292010 Flunamine is a Commodity code covering pharmaceutical products and drug-related supply items procured by state and local health agencies, counties, and multistate cooperative purchasing alliances. Recent state and local solicitations under this code focus on naloxone procurement, generic multi-source pharmaceuticals distributed through authorized wholesalers, and direct-to-manufacturer prescription programs. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing organizations like the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP). The work involves supplying finished pharmaceutical products with specified National Drug Codes, meeting cGMP and Drug Supply Chain Security Act compliance requirements, maintaining authorized distributor relationships, and delivering products to state and local health facilities on defined schedules.

Activity is concentrated in Florida and Minnesota, with Texas involvement in preliminary market research for pharmacy benefit innovation. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its community health building; the bid deadline was July 26, 2023. The Minnesota Department of Administration's MMCAP issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities, with proposals due March 26, 2026 and contract effectiveness July 1, 2026; vendors must maintain relationships with AmerisourceBergen, Cardinal Health, or Morris & Dickson and accept a 3 percent administrative fee. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer prescription program designed to bypass traditional pharmacy benefit managers and wholesalers. Vendors pursuing this code should expect multi-year terms, quarterly or ongoing delivery schedules, strict regulatory compliance requirements including FDA validation and insurance thresholds, and pricing models tied to net cost or competitively bid fixed rates.